{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:26Z","timestamp":1790913566759,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":203,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101335","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:49:39Z","timestamp":1785260979000},"page":"101335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rac\/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment"],"prefix":"10.1016","volume":"48","author":[{"given":"Anamaris","family":"Torres-Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-6806","authenticated-orcid":false,"given":"Stephanie","family":"Dorta-Estremera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor P.","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-1180","authenticated-orcid":false,"given":"Suranganie","family":"Dharmawardhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101335_bib0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101335_bib0002","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.18632\/aging.202264","article-title":"Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition","volume":"13","author":"Xiong","year":"2021","journal-title":"Aging (Albany. NY)"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101335_bib0003","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101335_bib0004","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101335_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112620","article-title":"Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation","volume":"42","author":"Zhang","year":"2023","journal-title":"Cell Rep."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101335_bib0006","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-3103","article-title":"Targeting pancreatic cancer metastasis by inhibition of Vav1, a driver of tumor cell invasion","volume":"75","author":"Razidlo","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0007","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12943-024-02128-2","article-title":"Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101335_bib0008","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/ph14070677","article-title":"Hacking pancreatic cancer: present and future of personalized medicine","volume":"14","author":"Di Federico","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101335_bib0009","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-23-0519","article-title":"KRAS-driven tumorigenesis and KRAS-driven therapy in pancreatic adenocarcinoma","volume":"23","author":"Than","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101335_bib0010","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.ctarc.2026.101335_bib0011","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS G12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101335_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1509319","article-title":"Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS\/MS","volume":"15","author":"Lu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101335_bib0013","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS (ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ctarc.2026.101335_bib0014","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour. Biol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12672-024-01256-x","article-title":"The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets","volume":"15","author":"Lorestani","year":"2024","journal-title":"Discov. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101335_bib0016","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/0008-5472.CAN-16-0442","article-title":"Macrophage-secreted tnf\u03b1 and TGF\u03b21 influence migration speed and persistence of cancer cells in 3D tissue culture via independent pathways","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0017","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cells9010046","article-title":"Current strategies to target tumor-associated macrophages to improve anti-tumor immune responses","volume":"9","author":"Anfray","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101335_bib0019","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-023-01388-7","article-title":"Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer","volume":"22","author":"Hussain","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101335_bib0021","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3390\/cancers14102429","article-title":"Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes","volume":"14","author":"Di Federico","year":"2022","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0022","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1038\/s41467-024-50450-6","article-title":"Necroptosis enhances 'don't eat me' signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis","volume":"15","author":"Liao","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0023","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-025-02529-x","article-title":"Targeting SERPINB3-MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy","volume":"25","author":"Huang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101335_bib0024","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-18-0619","article-title":"Targeting rac and Cdc42 GTPases in cancer","volume":"78","author":"Maldonado","year":"2018","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101335_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MPA.0000000000000276","article-title":"The role of p21-activated kinases in pancreatic cancer","volume":"44","author":"Yeo","year":"2015","journal-title":"Pancreas."},{"issue":"33","key":"10.1016\/j.ctarc.2026.101335_bib0026","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.3748\/wjg.v24.i33.3709","article-title":"p21-activated kinase signalling in pancreatic cancer: new insights into tumour biology and immune modulation","volume":"24","author":"Wang","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101335_bib0027","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4161\/cbt.20082","article-title":"The role of Rac1 in the regulation of NF-\u03bab activity, cell proliferation, and cell migration in non-small cell lung carcinoma","volume":"13","author":"Gastonguay","year":"2012","journal-title":"Cancer Biol. Ther."},{"issue":"28","key":"10.1016\/j.ctarc.2026.101335_bib0028","doi-asserted-by":"crossref","first-page":"11143","DOI":"10.1074\/jbc.RA118.003276","article-title":"Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42","volume":"293","author":"Razidlo","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101335_bib0029","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.molcel.2017.01.021","article-title":"The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2","volume":"65","author":"Hartwig","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ctarc.2026.101335_bib0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fcell.2020.00222","article-title":"Targeting Rho GTPase signaling networks in cancer","volume":"8","author":"Clayton","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"40","key":"10.1016\/j.ctarc.2026.101335_bib0031","doi-asserted-by":"crossref","first-page":"29105","DOI":"10.1074\/jbc.M113.510933","article-title":"FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas","volume":"288","author":"Licciulli","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2026.101335_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2057-z","article-title":"FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine","volume":"16","author":"Yeo","year":"2016","journal-title":"BMC. Cancer"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101335_bib0033","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1074\/jbc.M111.334524","article-title":"Characterization of EHop-016, novel small molecule inhibitor of rac GTPase","volume":"287","author":"Montalvo-Ortiz","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101335_bib0034","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1535-7163.MCT-16-0442","article-title":"Characterization of a dual Rac\/Cdc42 inhibitor MBQ-167 in metastatic cancer","volume":"16","author":"Humphries-Bickley","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101335_bib0035","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1535-7163.MCT-21-0348","article-title":"Efficacy of Rac and Cdc42 inhibitor MBQ-167 in triple-negative breast cancer","volume":"20","author":"Cruz-Collazo","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101335_bib0036","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1158\/2767-9764.CRC-22-0303","article-title":"Characterization of novel derivatives of MBQ-167, an inhibitor of the GTP-binding proteins rac\/Cdc42","volume":"2","author":"Medina","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101335_bib0037","doi-asserted-by":"crossref","first-page":"17981","DOI":"10.1021\/acsomega.9b01641","article-title":"Pharmacokinetics of the Rac\/Cdc42 inhibitor MBQ-167 in mice by supercritical fluid chromatography-tandem mass spectrometry","volume":"4","author":"Maldonado","year":"2019","journal-title":"ACS. Omega"},{"key":"10.1016\/j.ctarc.2026.101335_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1152458","article-title":"Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models","volume":"13","author":"Torres-Sanchez","year":"2023","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101335_bib0039","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1535-7163.MCT-23-0803","article-title":"Novel inhibition of central carbon metabolism pathways by Rac and CDC42 inhibitor MBQ167 and paclitaxel","volume":"23","author":"Cruz-Collazo","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2026.101335_bib0040","first-page":"OF1","article-title":"M6 metabolite contributes to the efficacy of the Rac\/Cdc42 inhibitor MBQ-167 in metastatic breast cancer","author":"Grafals-Ruiz","year":"2026","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101335_bib0041","doi-asserted-by":"crossref","first-page":"609","DOI":"10.18632\/aging.100804","article-title":"Rac1 GTPase in pancreatic cancer","volume":"7","author":"Yan","year":"2015","journal-title":"Aging (Albany. NY)"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101335_bib0042","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1053\/j.gastro.2014.08.032","article-title":"PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0043","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1152\/physrev.00045.2020","article-title":"Rho GTPase signaling in cancer progression and dissemination","volume":"102","author":"Crosas-Molist","year":"2022","journal-title":"Physiol. Rev."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101335_bib0044","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1042\/CS20191211","article-title":"Emerging roles for the IL-6 family of cytokines in pancreatic cancer","volume":"134","author":"van Duijneveldt","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ctarc.2026.101335_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1228907","article-title":"Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy","volume":"14","author":"Johansen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101335_bib0046","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2020.11.013","article-title":"Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine","volume":"501","author":"Xavier","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0047","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1186\/s12885-018-5161-4","article-title":"S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes","volume":"18","author":"Nedjadi","year":"2018","journal-title":"BMC. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101335_bib0048","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.prnil.2025.11.002","article-title":"Interleukin-6 secreted by tumor-associated macrophages promotes proliferation and migration through JAK2\/STAT3 signaling pathway in human prostate cancer cells","volume":"14","author":"Seok","year":"2026","journal-title":"Prostate Int."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101335_bib0049","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i10.109385","article-title":"Inflammatory biomarkers in the pathogenesis of pancreatic cancer: a literature review","volume":"16","author":"Aslam","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101335_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/6985703","article-title":"Calprotectin and calgranulin C as biomarkers of pancreatic tumors: baseline levels and level changes after surgery","volume":"2019","author":"Holub","year":"2019","journal-title":"Mediators. Inflamm."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101335_bib0051","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1172\/JCI136760","article-title":"Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix","volume":"130","author":"Jiang","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101335_bib0052","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2337\/db12-1148","article-title":"Rac1 signaling is required for insulin-stimulated glucose uptake and is dysregulated in insulin-resistant murine and human skeletal muscle","volume":"62","author":"Sylow","year":"2013","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101335_bib0053","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1083\/jcb.138.6.1265","article-title":"Localization of p21-activated kinase 1 (PAK1) to pinocytic vesicles and cortical actin structures in stimulated cells","volume":"138","author":"Dharmawardhane","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ctarc.2026.101335_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101329","article-title":"A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine","volume":"16","author":"He","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101335_bib0055","doi-asserted-by":"crossref","DOI":"10.1177\/15347354211073163","article-title":"Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia","volume":"21","author":"Goncalves","year":"2022","journal-title":"Integr. Cancer Ther."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:52:42Z","timestamp":1790913162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":55,"alternative-id":["S2468294226002467"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101335","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rac\/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101335"}}